Multiplex IHC and IF
Mosaic Laboratories offers multiplex brightfield immunohistochemistry and multiplex immunofluorescence assays to expand the power of your biomarker analyses. Performing multi-analyte immunohistochemistry has many potential benefits and applications in the field of drug target evaluation and patient screening, including: 1) determination and quantification of immunoreactivity co-localization; 2) evaluation of spatial relationships between immunoreactive cell types; 3) signal transduction pathway activation studies; 4) reduction in tissue depletion; and 5) decreased reagent utilization. Multiplex assays may be designed using multiplex chromogenic detection combined with multispectral imaging or immunofluorescence.
Sample Assays:
Ki-67 and phospho-histone H3 (pHH3)
Multiplexing of Ki-67 with pHH3 is used in pharmacodynamic biomarker studies of targeted mitotic inhibitors that arrest cells in mitotis. Ki-67 levels can help normalize differences between pre- and post-treatment biopsies that are due to biopsy location (e.g. hypoxic center vs. leading edge of cancer).
CD31 and phospho-ERK (pERK)
Multiplexing of pERK with CD31 is used in pharmacodynamic biomarker studies of anti-angiogenic agents. This multiplex provides quantitative evaluation of ERK activation within endothelia.
Drug Target plus Inflammatory Cell Markers
Multiplexing of an antibody toward your drug target and markers of immune response such as CD45, CD3, CD8, CD16 and CD68 allows evaluation of drug-induced immune response within solid tumors. These assays are used to assess the activity of therapeutic antibodies.
Custom Assay Development and Validation is Available upon Request